This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Prion Diseases  • Alert me on articles by topic

Carsten Korth, MD; Peter J. Peters, PhD

Arch Neurol. 2006;63:497-501.

Only a few years ago, pharmacotherapy of Creutzfeldt-Jakob disease was inconceivable. The enigmatic prion agent causing Creutzfeldt-Jakob disease, consisting solely of a misfolded conformational isoform, the scrapie prion protein, of the normal cellular prion protein was considered hard to treat by routine drug development. However, huge progress has been achieved in recent years, demonstrating principal reversibility of the neuropathological features and protection from clinical symptoms in animal models and introducing potential pharmaceutical agents. Among the most promising ones, antibodies have been shown to be protective against prion disease and heterocyclic small-molecule compounds have been proposed as antiprion lead compounds, initiating clinical trials.

Author Affiliations: Institute for Neuropathology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany (Dr Korth); and the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam (Dr Peters).